━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
SUMMARY: Could the positive results of the early Fluge & Mella 2011 blinded phase II rituximab trial and 2015 open label phase II study be due to inadvertently including some Giardia lamblia ME/CFS patients in the cohort, from the 2004 Bergen Giardia...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.